
Cancer immunologist challenging conventional thinking on advanced cancer. Targeting #cancer cachexia to help patients survive.
Joined January 2021
- Tweets7.5K
- Following430
- Followers1.3K
- Likes16.8K
Pinned Tweet
My book is out.
When the Body Turns Against Itself: A Patient's Guide to Cancer Cachexia.
Plain language. No jargon. Honest about what we know and what we don't.
For every family watching a loved one waste away.
amazon.com/dp/B0HKWZLF7P
Dr. Zhang, PhD retweeted
My book is out.
When the Body Turns Against Itself: A Patient's Guide to Cancer Cachexia.
Plain language. No jargon. Honest about what we know and what we don't.
For every family watching a loved one waste away.
amazon.com/dp/B0HKWZLF7P
If you're a patient fighting cachexia: you're not failing treatment. The field is still catching up. That's why I'm here.
1
52
That's the arc of this series: chemo works through your immune system; the tumor corrupts that same system; the corruption wastes you away; fixing the corruption is where the field must go.
3
60
Plain version for patients: if your care team offers only appetite pills or nutrition shakes for your wasting, you're allowed to ask what they're doing about the inflammation driving it. The field's best reviews are asking the same question.
2
46
The forward path we proposed: multimodal, biomarker-guided therapy — immunomodulators that restore immune balance rather than suppressing a single signal. Treat the disorder as a system, measure it in the patient, combine the tools.
4
260
Cachexia isn't a nutrition problem — the field now frames it as an immune-metabolic syndrome: tumor-host interaction, system-wide inflammation, organs failing together. You can't feed your way out of it, and one drug can't block your way out.
The track record is sobering: appetite stimulants, ghrelin agonists, single cytokine blockers, anabolics. None delivered lasting functional or survival benefit. My read: they all aimed at one molecule while the disease is a whole-system disorder.
1
1
135
This review I wrote with a Stanford collaborator. Its question: why has decades of cachexia drug development failed — and what should the field do instead?
3
216
If a broad immune correction worked in the lab, the bigger question is why cachexia drugs have failed patients for decades. Next week's paper — written with a Stanford collaborator — is our answer.
Why R-ketorolac? It's one mirror-image half of the familiar painkiller ketorolac — the half our program developed as an immunomodulator. Same starting molecule, different job: correcting an immune disorder, not killing pain.
3
215
Keep it honest: this is mouse data from our lab, not a treatment for people. What exists now is a clinical trial (NCT05336266) testing whether the same logic holds in patients. Science moves from cages to clinics — slowly, and carefully.
88
A wife watched her husband disappear — not from the tumor, but from the wasting. Day by day, his body seemed to vanish before her eyes, despite all the care he was getting. This is a story about cancer cachexia, and what happened when she refused to stop searching.
1
3
328
The lower dose was decided by his wife and me. The drug had been stopped because of side effects, not because it stopped working. That told us he was likely a super responder to it. He was treated at a lower dose, and his tumor responded.
1
1
47